Oncothyreon Inc (ONTY)
-NasdaqGS 1.80 
0.03(1.41%) 4:00PM EDT
| Prev Close: | 1.78 |
|---|
| Open: | 1.80 |
|---|
| Bid: | 1.65 x 100 |
|---|
| Ask: | 2.30 x 10000 |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | 0.88 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 1.77 - 1.82 |
|---|
| 52wk Range: | 1.65 - 6.24 |
|---|
| Volume: | 240,559 |
|---|
| Avg Vol (3m): | 873,948 |
|---|
| Market Cap: | 102.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ONCOTHYREON INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, Jun 14)
- Array/ONTY to Co-develop ARRY-380Zacks(Fri, May 31)
- Array BioPharma Inc Conference Call to discuss its Collaboration with Oncothyreon to Develop and Commercialize anti-HER2 Compound ARRY-380 scheduled for 10:00 am ET todayCCBN(Thu, May 30)
- Oncothyreon Announces $10 Million Registered Direct Offering to BVF Partners L.P.PR Newswire(Thu, May 30)
- Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380PR Newswire(Thu, May 30)
- Oncothyreon and Array Announce Collaboration to Develop and Commercialize Anti-HER2 Compound ARRY-380PR Newswire(Thu, May 30)
- ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements aEDGAR Online(Thu, May 30)
- Oncothyreon to Present at Jefferies 2013 Global Healthcare ConferencePR Newswire(Wed, May 29)
- Data on Merck KGaA's L-BLP25Zacks(Wed, May 22)
- What’s Moving These Biotech Stocks?at Motley Fool(Sun, May 19)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, May 19)
- This Week in Biotechat Motley Fool(Sat, May 18)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- Oncothyreon A Speculative Buyat Seeking Alpha(Fri, May 17)
- ONCOTHYREON INC. FinancialsEDGAR Online Financials(Fri, May 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | 08-May-95 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.59 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oncothyreon Inc, a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate is L-BLP25, a vaccine for the treatment of non-small cell lung cancer.
View More